DE69832730D1 - Methode zur behandlung von dopaminergen und gaba-nergen störungen - Google Patents

Methode zur behandlung von dopaminergen und gaba-nergen störungen

Info

Publication number
DE69832730D1
DE69832730D1 DE69832730T DE69832730T DE69832730D1 DE 69832730 D1 DE69832730 D1 DE 69832730D1 DE 69832730 T DE69832730 T DE 69832730T DE 69832730 T DE69832730 T DE 69832730T DE 69832730 D1 DE69832730 D1 DE 69832730D1
Authority
DE
Germany
Prior art keywords
gaba
hedgehog
nergenic
dopaminergen
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69832730T
Other languages
English (en)
Other versions
DE69832730T2 (de
Inventor
Ningning Miao
Monica Wang
K Mahanthappa
Kevin Pang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curis Inc
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Publication of DE69832730D1 publication Critical patent/DE69832730D1/de
Application granted granted Critical
Publication of DE69832730T2 publication Critical patent/DE69832730T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69832730T 1997-07-24 1998-07-24 Methode zur behandlung von dopaminergen und gaba-nergen störungen Expired - Fee Related DE69832730T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US900220 1997-07-24
US08/900,220 US7144997B2 (en) 1997-07-24 1997-07-24 Vertebrate embryonic patterning-inducing proteins, compositions and uses related therto
PCT/US1998/015419 WO1999004775A2 (en) 1997-07-24 1998-07-24 Method of treating dopaminergic and gaba-nergic disorders

Publications (2)

Publication Number Publication Date
DE69832730D1 true DE69832730D1 (de) 2006-01-12
DE69832730T2 DE69832730T2 (de) 2006-08-17

Family

ID=25412184

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69832730T Expired - Fee Related DE69832730T2 (de) 1997-07-24 1998-07-24 Methode zur behandlung von dopaminergen und gaba-nergen störungen

Country Status (10)

Country Link
US (3) US7144997B2 (de)
EP (2) EP1723950A2 (de)
JP (1) JP2001510796A (de)
AT (1) ATE311863T1 (de)
AU (1) AU8589398A (de)
CA (1) CA2297410A1 (de)
DE (1) DE69832730T2 (de)
DK (1) DK1067917T3 (de)
ES (1) ES2253822T3 (de)
WO (1) WO1999004775A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH114695A (ja) * 1997-04-25 1999-01-12 Hayashibara Biochem Lab Inc ヘッジホッグ蛋白質
AU8173098A (en) 1997-06-27 1999-01-19 Ontogeny, Inc. Neuroprotective methods and reagents
US7144997B2 (en) 1997-07-24 2006-12-05 Curis, Inc. Vertebrate embryonic patterning-inducing proteins, compositions and uses related therto
US6639051B2 (en) 1997-10-20 2003-10-28 Curis, Inc. Regulation of epithelial tissue by hedgehog-like polypeptides, and formulations and uses related thereto
AU1716599A (en) 1997-12-08 1999-06-28 Curis, Inc. Human patched genes and proteins, and uses related thereto
US7410798B2 (en) 2001-01-10 2008-08-12 Geron Corporation Culture system for rapid expansion of human embryonic stem cells
US6667176B1 (en) 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
US20030083242A1 (en) * 1998-11-06 2003-05-01 Alphonse Galdes Methods and compositions for treating or preventing peripheral neuropathies
US6884770B1 (en) 1998-11-06 2005-04-26 Curis, Inc. Methods and compositions for treating or preventing peripheral neuropathies
US20050042749A1 (en) 2001-05-16 2005-02-24 Carpenter Melissa K. Dopaminergic neurons and proliferation-competent precursor cells for treating Parkinson's disease
US7250294B2 (en) 2000-05-17 2007-07-31 Geron Corporation Screening small molecule drugs using neural cells differentiated from human embryonic stem cells
JP5943533B2 (ja) 2000-05-17 2016-07-06 アステリアス バイオセラピューティクス インコーポレイテッド 神経前駆細胞の集団
JP2002348239A (ja) * 2000-10-05 2002-12-04 Takeda Chem Ind Ltd 幹細胞・神経前駆細胞の増殖・分化促進剤
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
EP2221377B2 (de) * 2002-02-01 2017-05-17 Life Technologies Corporation Doppelsträngige Oligonukleotide
EP1670901A4 (de) * 2003-08-29 2007-09-05 Wisconsin Alumni Res Found Verfahren zur in-vitro-differenzierung von neuralen stammzellen, motorneuronen und dopaminneuronen aus embryonalen primatenstammzellen
WO2005061002A2 (en) * 2003-12-19 2005-07-07 Curis, Inc. Composition and methods for modulating cns activity
WO2006020996A2 (en) 2004-08-11 2006-02-23 Cedars-Sinai Medical Center Treatment of parkinson's disease and related disorders
US7858590B2 (en) 2005-08-11 2010-12-28 Cedars-Sinai Medical Center Treatment of parkinson's disease and related disorders
US20140248696A1 (en) * 2013-03-01 2014-09-04 Wisconsin Alumni Research Foundation Methods of maintaining, expanding, and diffrentiating neuronal subtype specific progenitors
US10160950B2 (en) 2013-03-01 2018-12-25 Wisconsin Alumni Research Foundation Methods of maintaining, expanding and differentiating neuronal subtype specific progenitors
WO2018129421A1 (en) * 2017-01-09 2018-07-12 Genervon Biopharmaceuticals, LLC A promising drug candidate for parkinson's disease

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456687A (en) 1978-11-16 1984-06-26 President And Fellows Of Harvard College Agents for promoting growth of epithelial cells
EP0187371B1 (de) 1984-12-27 1991-06-19 Asahi Kasei Kogyo Kabushiki Kaisha Substituierte Isochinolinsulfonyl-Verbindungen
EP0249873B1 (de) 1986-06-16 1993-07-28 Daiichi Pharmaceutical Co., Ltd. Therapeutisches Mittel für Hautgeschwüre
JPH0745383B2 (ja) 1986-09-30 1995-05-17 第一製薬株式会社 環状アデノシン誘導体含有毛髪用剤
JP3771253B2 (ja) 1988-09-02 2006-04-26 ダイアックス コープ． 新規な結合タンパク質の生成と選択
DE3942114C2 (de) 1988-12-26 1997-09-04 Hiroyoshi Hidaka Verbindungen mit einer Wirkung für eine gleichmäßige Gefäßmuskelentspannung und pharmazeutische Zusammensetzung, die diese enthält
EP0464206A4 (en) 1989-03-24 1992-05-13 Daiichi Pharmaceutical Co., Ltd. Drug for improving brain function
JPH02273610A (ja) 1989-04-17 1990-11-08 Chugai Pharmaceut Co Ltd 発毛促進剤
JPH0725786A (ja) 1990-05-16 1995-01-27 Univ Rockefeller アルツハイマー病を伴うアミロイドーシスの治療
JPH04305528A (ja) 1991-02-22 1992-10-28 Dai Ichi Seiyaku Co Ltd ケラチノサイト及び皮膚線維芽細胞の増殖刺激剤
ES2330052T3 (es) 1991-03-01 2009-12-03 Dyax Corporation Proteina quimerica que comprende micro-proteinas que tienen dos o mas puentes disulfuro y relaizaciones de las mismas.
US5223408A (en) 1991-07-11 1993-06-29 Genentech, Inc. Method for making variant secreted proteins with altered properties
CA2123096A1 (en) 1991-11-08 1993-05-13 Beat J. Knusel Compositions containing k-252 compounds for potentiation of neurotrophin activity
US5461146A (en) 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
JP2893029B2 (ja) 1992-08-10 1999-05-17 旭化成工業株式会社 心臓保護剤
US6333168B1 (en) 1993-05-20 2001-12-25 The Trustees Of Columbia University In The City Of New York Cloning, expression and uses of dorsalin-1
US5519035A (en) 1993-07-02 1996-05-21 Cornell Research Foundation, Inc. Treatment of stroke or in anticipation of the occurrence of brain ischemia
US5789543A (en) 1993-12-30 1998-08-04 President And Fellows Of Harvard College Vertebrate embryonic pattern-inducing proteins and uses related thereto
US6610656B1 (en) * 1993-12-30 2003-08-26 President And Fellows Of Harvard College Method of promoting chondrocyte differentiation with hedgehog related polypeptides
US20030186357A1 (en) * 1993-12-30 2003-10-02 Philip W. Ingham Vertebrate embryonic pattern-inducing proteins, and uses related thereto
US7060450B1 (en) * 1993-12-30 2006-06-13 President And Fellows Of Harvard College Screening assays for agonists and antagonists of the hedgehog signaling pathway
AU704178B2 (en) 1993-12-30 1999-04-15 Imperial Cancer Research Technology Ltd Vertebrate embryonic pattern-inducing hedgehog-like proteins
US6271363B1 (en) * 1993-12-30 2001-08-07 President & Fellows Of Harvard College Nucleic acids encoding hedgehog proteins
US6884775B1 (en) * 1993-12-30 2005-04-26 President And Fellows Of Harvard College Methods and compositions for regulating skeletogenic formation
US6165747A (en) * 1993-12-30 2000-12-26 President & Fellows Of Harvard College Nucleic acids encoding hedgehog proteins
US6261786B1 (en) * 1993-12-30 2001-07-17 Imperial Cancer Res. Technology Screening assays for hedgehog agonists and antagonists
CA2184092A1 (en) 1994-02-25 1995-08-31 Thomas M. Jessell Dna encoding the vertebrate homolog of hedgehog, vhh-1, expressed by the notochord, and uses thereof
US5585087A (en) 1994-06-08 1996-12-17 President And Fellows Of Harvard College Assay for identifying extracellular signaling proteins
US5554608A (en) 1994-09-28 1996-09-10 Ahluwalia; Gurpreet S. Inhibition of hair growth
US6027882A (en) * 1994-10-07 2000-02-22 The Regents Of The University Of California Patched genes and their use for diagnostics
US6946257B1 (en) * 1994-10-07 2005-09-20 Regents Of The University Of California Patched genes and uses related thereto
EP1616942A3 (de) * 1994-10-07 2006-11-22 The Board Of Trustees Of The Leland Stanford Junior University Patched Gene und ihre Verwendung
US6429354B1 (en) * 1994-10-07 2002-08-06 The Board Of Trustees Of The Leland Stanford Junior University Patched genes and uses related thereto
US6281332B1 (en) 1994-12-02 2001-08-28 The Johns Hopkins University School Of Medicine Hedgehog-derived polypeptides
US5643915A (en) 1995-06-06 1997-07-01 Andrulis Pharmaceuticals Corp. Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies
WO1997011095A1 (en) 1995-09-21 1997-03-27 The Trustees Of Columbia University In The City Of New York Uses of bone morphogenetic proteins
WO1998012326A1 (en) 1996-09-20 1998-03-26 President And Fellows Of Harvard College Hedgehog interacting proteins and uses related thereto
US5990281A (en) 1996-09-30 1999-11-23 Genentech, Inc. Vertebrate smoothened proteins
JP2002503088A (ja) 1996-10-07 2002-01-29 ザ ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン 新規ヘッジホッグ由来ポリペプチド
US5759811A (en) 1996-11-13 1998-06-02 The Regents Of The University Of California Mutant human hedgehog gene
JPH10194987A (ja) 1997-01-14 1998-07-28 Youtai Iwamoto 骨・軟骨形成用組成物
WO1998035020A2 (en) 1997-02-10 1998-08-13 The Presidents And Fellows Of Harvard College Methods for modulating hematopoiesis and vascular growth
JPH114695A (ja) 1997-04-25 1999-01-12 Hayashibara Biochem Lab Inc ヘッジホッグ蛋白質
EP0879888A3 (de) 1997-05-23 1999-07-14 Smithkline Beecham Plc Patched-2 Polypeptide und Polynucleotide und Methoden zu ihrer Herstellung
AU8173098A (en) * 1997-06-27 1999-01-19 Ontogeny, Inc. Neuroprotective methods and reagents
US6218144B1 (en) 1997-06-30 2001-04-17 The Board Of Trustees Of The Leland Stanford Junior University Costal2 genes and their uses
WO1999001468A2 (en) 1997-07-01 1999-01-14 Ontogeny, Inc. Vertebrate smoothened gene, gene products, and uses related thereto
US7144997B2 (en) 1997-07-24 2006-12-05 Curis, Inc. Vertebrate embryonic patterning-inducing proteins, compositions and uses related therto
AU9125298A (en) 1997-08-29 1999-03-16 Ontogeny, Inc. Regulation of muscle tissues by hedgehog-like polypeptides, and formulations and uses related thereto
US20020026043A1 (en) 1998-02-06 2002-02-28 Brian Taylor Edmonds Desert hedgehog related nucleic acids and proteins

Also Published As

Publication number Publication date
EP1067917B1 (de) 2005-12-07
DK1067917T3 (da) 2006-04-18
US20030119729A1 (en) 2003-06-26
US20020045206A1 (en) 2002-04-18
ATE311863T1 (de) 2005-12-15
JP2001510796A (ja) 2001-08-07
US7138492B2 (en) 2006-11-21
ES2253822T3 (es) 2006-06-01
US7144997B2 (en) 2006-12-05
EP1067917A2 (de) 2001-01-17
EP1723950A2 (de) 2006-11-22
CA2297410A1 (en) 1999-02-04
US20070048286A1 (en) 2007-03-01
WO1999004775A9 (en) 1999-04-29
AU8589398A (en) 1999-02-16
DE69832730T2 (de) 2006-08-17
WO1999004775A3 (en) 2000-11-23
WO1999004775A2 (en) 1999-02-04

Similar Documents

Publication Publication Date Title
DE69832730D1 (de) Methode zur behandlung von dopaminergen und gaba-nergen störungen
DE69839014D1 (de) Apolipoprotein a-i agonisten und deren verwendung zur behandlung dyslipidämischer erkrankungen
DE69829412D1 (de) Hemmung der raf-kinase unter verwendung von symmetrisch und unsymmetrisch substituierten harnstoffen
DE69836752D1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
DE58902094D1 (de) Kombinationspraeparat zur behandlung von nervenzell-und nervenfasererkrankungen und verletzungen.
DE3687069D1 (de) Verwendung von 3'-azido-3'-deoxythymidin zur behandlung oder vorbeugung von menschlichen retrovirus-infektionen.
DE10199020I1 (de) Galanthamin oder dessen Analoge zur Behandlung der Alzheimerschen Krankheit
DE69830513D1 (de) HEMMUNG DER p38 KINASE UNTER VERWENDUNG VON SYMMETRISCHEN UND ASYMMETRISCHEN DIPHENYLHARNSTOFFEN
DE68908971D1 (de) Verwendung von physiologisch wirksamen Substanzen zur Herstellung von Medikamenten für Gehirn- und Nervenerkrankungen.
DE3886254D1 (de) Apparat zur Behandlung von biologischen Proben und Behandlungsmethoden mit dem Apparat.
DE69435038D1 (de) Aktivin rezeptor-ähnliche kinase (alk), gehörend zur tgf rezeptorfamilie und/oder zur bmp rezeptorfamilie
ATE95064T1 (de) Verwendung von angiotensin-converting-enzyminhibitoren zur behandlung von atherosklerose, thrombose und der peripheren gefaesskrankheit.
ATE433461T1 (de) Rana pipiens proteine und deren verwendung in der behandlung von tumoren
ATE257708T1 (de) Kombinationen enthaltend vx478, zidovudin und 3tc zur behandlung von hiv
DE69729735D1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
DE3852625D1 (de) Vektoren und Verbindungen zur Expression von Zymogen-Formen von menschlichem Protein C.
DE69924284D1 (de) Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten
DE69931390D1 (de) Verfahren unfd zusammensetzungen zur behandlung von krankheiten bei denen exitotoxizität beteiligt ist
DE69004301T2 (de) Mischung zur Behandlung der von exokrinen Insuffizienz der Bauchspeicheldrüse und die Verwendung der genannten Mischung.
ATA412084A (de) Vorrichtung zur kultivierung und behandlung von biokatalysatoren
DE3787954D1 (de) Verwendung von 5-(Subst. Phenyl)- Oxazolidinonderivaten zur Behandlung von Depressionen.
DE60016183D1 (de) Verfahren zur verwendung von viraler replicase
DE69926996D1 (de) Verwendung von riluzol zur behandlung der retinalischemie
DE59410340D1 (de) Verwendung von Bradykinin-Antagonisten zur Behandlung von Viruserkrankungen
DE59609836D1 (de) Verwendung von zuckertensiden zur behandlung von ledern und pelzen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee